Skip to content
Screener

4D Molecular Therapeutics FDMT Other Non-Current Liabilities

Other Non-Current Liabilities at other companies

Eli Lilly logo
Eli LillyLLY
$7.34B+213%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.28B+34.1%
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$1.26B+5.4%
EyePoint, Inc. logo
EyePoint, Inc.EYPT
$23K-84.5%
AbbVie logo
AbbVieABBV
$34.11B+9.4%
Regenxbio logo
RegenxbioRGNX
$486K-26.8%

Other financials

Income statement

See full
Revenue$3.0M+21,664%
Operating income-$73.6M-37.3%
Net income-$68.8M-43.3%
EPS (diluted)-$1.01-17.4%

Balance sheet

See full
Cash & equivalents$72.5M-45.7%
Total debt$20.5M-13.9%
Total equity$451.8M-3.8%
Total assets$512.9M-0.5%

Cash flow

See full
Operating cash flow-$68.1M-42.6%
CapEx--100%
Free cash flow-$68.1M-40.8%

Valuation

See full
Market cap$561.97M+127%
Enterprise value$510.02M+162%
P/S6.4×-7,487×

Profitability

See full
Operating margin-220.1%-110pp
Net margin-174,314.2%-62,763pp
FCF margin-154,209.2%-53,057pp

Returns & leverage

See full
Return on equity-45.4%+29.8pp
Debt / equity0×0.0×
Current ratio9.3×-3.0×

Where this comes from

Reported directly by 4D Molecular Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.

The source filing: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211939
Line itemMarch 31,2026December 31,2025
Deferred revenue, net of current portion2,125745
Derivative liability370358
Operating lease liabilities, long-term portion15,04915,821
Other liabilities121138
Total liabilities61,06961,047
Commitments and contingencies (Note 8)
Stockholders’ equity
Preferred stock, $0.0001 par value, 10,000,000 shares authorized at March 31, 2026 and December 31, 2025; no shares issued and outstanding at March 31, 2026 and December 31, 2025——

Item 1. Condensed Financial Statements (Unaudited)

FAQ

What is 4D Molecular Therapeutics's other non-current liabilities?
4D Molecular Therapeutics (FDMT) reported other non-current liabilities of $121K in Q1 2026.
How has 4D Molecular Therapeutics's other non-current liabilities changed year-over-year?
4D Molecular Therapeutics's other non-current liabilities decreased by 31.6% year-over-year, from $177K to $121K.
What is the long-term trend for 4D Molecular Therapeutics's other non-current liabilities?
Over 5 years (2020 to 2025), 4D Molecular Therapeutics's other non-current liabilities has grown at a -40.5% compound annual growth rate (CAGR), from $1.85M to $138K.
What does other non-current liabilities mean?
Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.

Ask your AI about 4D Molecular Therapeutics's other non-current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude